April 23 (Reuters) - AbbVie ( ABBV ) said on Thursday

the U.S. Food and Drug Administration has declined to approve

its experimental wrinkle treatment, citing issues in

manufacturing.

The company said the agency did not raise concerns about the

treatment's safety or efficacy, and did not ask for new patient

studies.

TrenibotE is a fast-acting botulinum toxin aimed at treating

facial wrinkles such as frown lines, and it is designed to wear

off more quickly than traditional Botox treatments.

The company said the treatment has been studied in more than

2,100 patients, including two late-stage trials and a safety

study.